Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD

BMC Pulmonary Medicine

Volumn 14, Issue 1, 2014, Pages

  Singh, Dave ^a   Nicolini, Gabriele ^b   Bindi, Eddi ^b   Corradi, Massimo ^c   Guastalla, Daniele ^b   Kampschulte, Jorg ^d   Pierzchała, Władysław ^e   Sayiner, Abdullah ^f   Szilasi, Mária ^g   Terzano, Claudio ^h   Vestbo, Jørgen ^a,i  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHIESI FARMACEUTICI S P A   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d Praxis Dr Jorg Kampschulte Wulffstrasse 7   (Germany)

^e Praxis Dr Jorg Kampschulte Wulffstrasse 7 ^*  (Poland)

^f EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^g UNIVERSITY OF DEBRECEN   (Hungary)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACCUHALER; BECLOMETHASONE PLUS FORMOTEROL; BRONCHODILATING AGENT; FLUTICASONE PROPIONATE PLUS SALMETEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; FOSTER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY POWDER INHALER; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MULTICENTER STUDY; OUTCOME ASSESSMENT; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ALBUTEROL; ANDROSTADIENES; BECLOMETHASONE; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84897528708     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-14-43     Document Type: Article

References (41)

1. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease, GOLD Executive Summary. Am J Respir Crit Care Med 2013, 187(4):347-365. 10.1164/rccm.201204-0596PP, 10.1164/rccm.201204-0596PP, 22878278.
2. Kessler R, Partridge MR, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D, Ostinelli J. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011, 37(2):264-272. 10.1183/09031936.00051110, 21115606.
3. Dong YH, Lin HH, Shau WY, Wu YC, Chang CH, Lai MS. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomized controlled trials. Thorax 2013, 68(1):48-56. 10.1136/thoraxjnl-2012-201926, 23042705.
4. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002, 19:182-191. 10.1183/09031936.02.00283202, 11843317.
5. Caramori G, Ito K, Papi A, Adcock IM. Interactions between long-acting β2 agonists and glucocorticoids. Drug Discov Today Ther Strateg 2006, 3:261-268.
6. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008, 300(20):2407-2416. 10.1001/jama.2008.717, 19033591.
7. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009, 169:219-229. 10.1001/archinternmed.2008.550, 19204211.
8. Singh S, Loke YK. Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Curr Opin Pulm Med 2010, 16:118-122. 10.1097/MCP.0b013e328334c085, 2908947, 19926996.
9. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2) agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012, 12(9):CD006829.
10. Singh D, Kampschulte J, Wedzicha JA, Jones PW, Cohuet G, Corradi M, Higenbottam T, Petruzzelli S, Vestbo J. A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations. Eur Respir J 2013, 41(1):12-17. 10.1183/09031936.00207611, 22653766.
11. Calverley PM, Kuna P, Monsó E, Costantini M, Petruzzelli S, Sergio F, Varoli G, Papi A, Brusasco V. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respir Med 2010, 104:1858-1868. 10.1016/j.rmed.2010.09.008, 20965712.
12. Cazzola M, Paggiaro P, Palange P, Bjermer L, Ausin P, Carlsson LG, Ekelund J, Lotvall J. Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study. Clin Drug Investig 2012, 32(3):147-155. 10.2165/11630880-000000000-00000, 22235841.
13. Lindberg A, Szalai Z, Pullerits T, Radeczky E. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction. Respirology 2007, 12:732-739. 10.1111/j.1440-1843.2007.01132.x, 17875063.
14. Partridge MR, Schuermann W, Beckman O, Persson T, Polanowski T. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis 2009, 3(4):1-11.
15. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984, 85:751-758. 10.1378/chest.85.6.751, 6723384.
16. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005, 2:319-338.
17. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure for chronic airflow limitation - the St George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145:1321-1327. 10.1164/ajrccm/145.6.1321, 1595997.
18. Schünemann HJ, Griffith L, Jaeschke R, Goldstein R, Stubbing D, Guyatt GH. Evaluation of the minimal important difference for the feeling thermometer and the St George's Respiratory Questionnaire in patients with chronic airflow obstruction. J Clin Epidemiol 2003, 56:1170-1176. 10.1016/S0895-4356(03)00115-X, 14680667.
19. Statement ATS. Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166:111-117.
20. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789. 10.1056/NEJMoa063070, 17314337.
21. Witek TJ, Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003, 56:248-255. 10.1016/S0895-4356(02)00589-9, 12725879.
22. Witek TJ, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003, 21:267-272. 10.1183/09031936.03.00068503a, 12608440.
23. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009, 25(8):2043-2048. 10.1185/03007990903103006, 19569976.
24. Van Noord JA, Smeets JJ, Raaijmakers JA, Bommer AM, Maesen FP. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996, 9(8):1684-1688. 10.1183/09031936.96.09081684, 8866595.
25. Kottakis J, Cioppa GD, Creemers J, Greefhorst L, Lecler V, Pistelli R, Overend T, Till D, Rapatz G, Le Gros V, Bouros D, Siafakas N. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can Respir J 2002, 9(2):107-115.
26. Bouros D, Kottakis J, Le Gros V, Overend T, Della Cioppa G, Siafakas N. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility. Curr Med Res Opin 2004, 20(5):581-586. 10.1185/030079904125003368, 15140323.
27. Cazzola M, Santus P, Di Marco F, Boveri B, Castagna F, Carlucci P, Matera MG, Centanni S. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD. Respir Med 2003, 97(5):453-457. 10.1053/rmed.2002.1455, 12735659.
28. Celik G, Kayacan O, Beder S, Durmaz G. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action. Respiration 1999, 66(5):434-439. 10.1159/000029427, 10516540.
29. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 2008, 63(9):831-838. 10.1136/thx.2007.086041, 18728206.
30. Cazzola M, Page CP, Rogliani P, Matera MG. β2-agonist therapy in lung disease. Am J Respir Crit Care Med 2013, 187(7):690-696. 10.1164/rccm.201209-1739PP, 23348973.
31. Nicolini G, Scichilone N, Bizzi A, Papi A, Fabbri LM. Beclomethasone/formoterol fixed combination for the management of asthma: patient considerations. Ther Clin Risk Manag 2008, 4:855-864. 2621423, 19209268.
32. Scichilone N, Battaglia S, Sorino C, Paglino G, Martino L, Paternò A, Santagata R, Spatafora M, Nicolini G, Bellia V. Effects of extra-fine inhaled beclomethasone/formoterol on both large and small airways in asthma. Allergy 2010, 65:897-902. 10.1111/j.1398-9995.2009.02306.x, 20121764.
33. Papi A, Paggiaro PL, Nicolini G, Vignola AM, Fabbri LM. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J 2007, 29:682-689. 10.1183/09031936.00095906, 17107988.
34. Huchon G, Magnussen H, Chuchalin A, Dymek L, Gonod FB, Bousquet J. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med 2009, 103:41-49. 10.1016/j.rmed.2008.09.002, 18977646.
35. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Paré PD. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350(26):2645-2653. 10.1056/NEJMoa032158, 15215480.
36. Tzani P, Crisafulli E, Nicolini G, Aiello M, Chetta A, Clini EM, Olivieri D. Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients. Int J Chron Obstruct Pulmon Dis 2011, 6:503-509. 3206766, 22069361.
37. Allen & Hanburys Seretide 100, 250, 500 Accuhaler. 2012, Available from URL: http://emc.medicines.org.uk, Allen & Hanburys.
38. Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T. The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003, 124:834-843. 10.1378/chest.124.3.834, 12970006.
39. Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008, 102(8):1099-1108. 10.1016/j.rmed.2008.04.019, 18614347.
40. Anzueto A, Ferguson GT, Feldman G, Chinsky K, Seibert A, Emmett A, Knobil K, O'Dell D, Kalberg C, Crater G. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 2009, 6(5):320-329. 10.1080/15412550903140881, 19863361.
41. Glaxo SK. Advair DiskusR 100/50, 250/50, 500/50 prescribing information [online]. 2012, Available from URL: http://us.gsk.com/products/assets/us_advair.pdf [Accessed 2012 Nov 21].